Antonio Vallano Ferraz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4142579/publications.pdf

Version: 2024-02-01

57 papers

1,778 citations

279798 23 h-index 289244 40 g-index

86 all docs 86 docs citations

86 times ranked 2309 citing authors

#	Article	IF	CITATIONS
1	Obstacles and solutions for spontaneous reporting of adverse drug reactions in the hospital. British Journal of Clinical Pharmacology, 2005, 60, 653-658.	2.4	155
2	Inhaled antibiotic therapy in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa. Respiratory Medicine, 1999, 93, 476-480.	2.9	142
3	Regulatory Framework for Advanced Therapy Medicinal Products in Europe and United States. Frontiers in Pharmacology, 2019, 10, 921.	3.5	111
4	A critical review of guidelines for low back pain treatment. European Spine Journal, 2006, 15, 543-553.	2.2	93
5	Prevalence, risk factors and main features of adverse drug reactions leading to hospital admission. European Journal of Clinical Pharmacology, 2014, 70, 361-367.	1.9	86
6	Multicenter hospital study on prescribing patterns for prophylaxis and treatment of complications of cirrhosis. European Journal of Clinical Pharmacology, 2002, 58, 435-440.	1.9	72
7	An Intervention to Improve Spontaneous Adverse Drug Reaction Reporting by Hospital Physicians. Drug Safety, 2009, 32, 77-83.	3.2	67
8	Inappropriate prescribing to the oldest old patients admitted to hospital: prevalence, most frequently used medicines, and associated factors. BMC Geriatrics, 2015, 15, 42.	2.7	67
9	Assessment of Antibiotic Prescription in Acute Respiratory Infections in Adults. Journal of Infection, 2000, 41, 73-83.	3.3	58
10	Inappropriate prescribing to older patients admitted to hospital: A comparison of different tools of misprescribing and underprescribing. European Journal of Internal Medicine, 2014, 25, 710-716.	2.2	47
11	Use of venous thromboprophylaxis and adherence to guideline recommendations: a cross-sectional study. Thrombosis Journal, 2004, 2, 3.	2.1	43
12	Prevalence of pain in adults admitted to Catalonian hospitals: A cross-sectional study. European Journal of Pain, 2006, 10, 721-721.	2.8	43
13	Non-inferiority of dose reduction versus standard dosing of TNF-inhibitors in axial spondyloarthritis. Arthritis Research and Therapy, 2019, 21, 11.	3.5	42
14	Appropriateness of antibiotic prescriptions in community-acquired acute pediatric respiratory infections in Spanish emergency rooms. Pediatric Infectious Disease Journal, 2001, 20, 751-758.	2.0	41
15	Implementing reflective multicriteria decision analysis (MCDA) to assess orphan drugs value in the Catalan Health Service (CatSalut). Orphanet Journal of Rare Diseases, 2019, 14, 157.	2.7	37
16	Utilisation of antihyperglycaemic drugs in ten European countries: different developments and different levels. Diabetologia, 2006, 49, 2024-2029.	6.3	36
17	Reporting randomised clinical trials of analgesics after traumatic or orthopaedic surgery is inadequate: a systematic review. BMC Clinical Pharmacology, 2010, 10, 2.	2.5	36
18	Medical speciality and pattern of medicines prescription. European Journal of Clinical Pharmacology, 2004, 60, 725-730.	1.9	33

#	Article	IF	Citations
19	Comparison of regulatory pathways for the approval of advanced therapies in the European Union and the United States. Cytotherapy, 2021, 23, 261-274.	0.7	33
20	Levetiracetam-Induced Drug Reaction with Eosinophilia and Systemic Symptoms Syndrome. Annals of Pharmacotherapy, 2012, 46, e20-e20.	1.9	32
21	Assessment of antibiotic prescription in acute urinary tract infections in adults. Journal of Infection, 2007, 54, 235-244.	3.3	31
22	Drug use for non-hepatic associated conditions in patients with liver cirrhosis. European Journal of Clinical Pharmacology, 2003, 59, 71-76.	1.9	30
23	Management of postoperative pain in abdominal surgery in Spain. A multicentre drug utilization study. British Journal of Clinical Pharmacology, 1999, 47, 667-673.	2.4	28
24	Effect of an intervention on the features of adverse drug reactions spontaneously reported in a hospital. European Journal of Clinical Pharmacology, 2010, 66, 937-945.	1.9	24
25	G protein-coupled receptor oligomerization for what?. Journal of Receptor and Signal Transduction Research, 2010, 30, 322-330.	2.5	22
26	Outcomes of off-label drug uses in hospitals: a multicentric prospective study. European Journal of Clinical Pharmacology, 2014, 70, 1385-1393.	1.9	22
27	An Update on Adenosine A2A Receptors as Drug Target in Parkinson's Disease. CNS and Neurological Disorders - Drug Targets, 2011, 10, 659-669.	1.4	22
28	Trends in lithium prescription in Spain from 1985 to 2003. Journal of Affective Disorders, 2006, 91, 273-276.	4.1	20
29	Potentially Inappropriate Antihypertensive Prescriptions to Elderly Patients: Results of a Prospective, Observational Study. Drugs and Aging, 2017, 34, 453-466.	2.7	20
30	Have We Improved Pain Control in Cancer Patients? A Multicenter Study of Ambulatory and Hospitalized Cancer Patients. Journal of Palliative Medicine, 2015, 18, 923-932.	1.1	19
31	Use of non-specific intravenous human immunoglobulins in Spanish hospitals; need for a hospital protocol. European Journal of Clinical Pharmacology, 2010, 66, 633-641.	1.9	18
32	Available evidence and outcome of off-label use of rituximab in clinical practice. European Journal of Clinical Pharmacology, 2013, 69, 1689-1699.	1.9	16
33	Analgesic use and pain in the hospital settings. European Journal of Clinical Pharmacology, 2007, 63, 619-626.	1.9	15
34	The variability and appropriateness of the antibiotic prescription of acute otitis media in childhood. International Journal of Pediatric Otorhinolaryngology, 2000, 56, 175-184.	1.0	13
35	Analgesics for pain after traumatic or orthopaedic surgery: what is the evidence-a systematic review. European Journal of Clinical Pharmacology, 2006, 62, 971-988.	1.9	12
36	An inter-rater reliability study of the prescribing indicated medications quality indicators of the Assessing Care Of Vulnerable Elders (ACOVE) 3 criteria as a potentially inappropriate prescribing tool. Archives of Gerontology and Geriatrics, 2014, 58, 460-464.	3.0	11

#	Article	IF	Citations
37	Evaluation of dose reduction versus standard dosing for maintenance of remission in patients with spondyloarthritis and clinical remission with anti-TNF (REDES-TNF): study protocol for a randomized controlled trial. Trials, 2015, 16, 370.	1.6	11
38	Elderly patients treated with psychotropic medicines admitted to hospital: associated characteristics and inappropriate use. European Journal of Clinical Pharmacology, 2016, 72, 755-764.	1.9	11
39	Chronic obstructive pulmonary disease (COPD) in Spain and the different aspects of its social impact: a multidisciplinary opinion document. Revista Espanola De Quimioterapia, 2020, 33, 49-67.	1.3	11
40	Methodological Characteristics of Clinical Trials Supporting the Marketing Authorisation of Advanced Therapies in the European Union. Frontiers in Pharmacology, 2021, 12, 773712.	3.5	9
41	Drug-Induced Lupus-Like Reaction and Captopril. Annals of Pharmacotherapy, 1993, 27, 1541-1542.	1.9	7
42	Multicentre hospital drug utilization study on the prophylaxis of venous thromboembolism. The Venous Thromboembolism Study Group of the Spanish Society of Clinical Pharmacology British Journal of Clinical Pharmacology, 1994, 37, 255-259.	2.4	7
43	Use of $\hat{l}\pm 2$ -Adrenergic Agonists to Improve Surgical Field Visibility in Endoscopy Sinus Surgery: A Systematic Review of Randomised Controlled Trials. Clinical Therapeutics, 2018, 40, 136-149.e19.	2.5	7
44	Editorial Comment: European guidelines for low back pain – A necessary step forward and an opportunity not to be missed. European Spine Journal, 2006, 15, s131-s133.	2.2	6
45	Educational sessions in pharmacovigilance: What do the doctors think?. BMC Research Notes, 2010, 3, 311.	1.4	6
46	Hurdles of environmental risk assessment procedures for advanced therapy medicinal products: comparison between the European Union and the United States. Critical Reviews in Toxicology, 2019, 49, 580-596.	3.9	6
47	Hospital DoctorsÃ,' Views and Concerns about Pharmacovigilance. Journal of Pharmacovigilance, 2015, 03, .	0.2	4
48	Prescripción de medicamentos genéricos en pacientes dados de alta de un servicio hospitalario de urgencias. Medicina ClÃnica, 2003, 121, 645-649.	0.6	3
49	New Developments in Therapeutic Agents for Legionnaires Disease. Anti-Infective Agents in Medicinal Chemistry, 2007, 6, 228-242.	0.6	2
50	Tratamiento antimicrobiano de las infecciones bronquiales en los servicios de urgencias hospitalarios. Anales De PediatrÃa, 2004, 61, 143-149.	0.2	2
51	Use of heparin for the prevention of venous thromboembolism. Pharmacoepidemiology and Drug Safety, 1994, 3, 211-214.	1.9	1
52	Therapeutic enquiries about biological agents as a tool to identify safety aspects and patterns of use. European Journal of Hospital Pharmacy, 2016, 23, 161-165.	1,1	1
53	Observational study of post-operative pain control before and after the implementation of a clinical practice guideline for postoperative pain management. Medicina ClĀnica (English Edition), 2019, 153, 312-318.	0.2	O
54	Methodological features of pivotal clinical trials for the current authorised advanced therapies medicinal products in the european union. Cytotherapy, 2021, 23, S200.	0.7	0

#	Article	IF	CITATIONS
55	Estudio observacional del control del dolor postoperatorio antes y después de la implementación de una guÃa del manejo del dolor postoperatorio. Medicina ClÃnica, 2019, 153, 312-318.	0.6	O
56	Actualización en el tratamiento farmacológico de la artrosis. Atencion Primaria, 2003, 31, 264-268.	1.4	0
57	Actualización en la prevención de las úlceras gastroduodenales inducidas por antiinflamatorios no esteroideos y sus complicaciones. Atencion Primaria, 2003, 32, 55-59.	1.4	O